<DOC>
	<DOCNO>NCT02531217</DOCNO>
	<brief_summary>The purpose study assess safety tolerability profile ATYR1940 treatment adult patient molecularly define genetic muscular dystrophy .</brief_summary>
	<brief_title>Safety , Tolerability , PK , Activity ATYR1940 Patients With Muscular Dystrophy - Study Extension</brief_title>
	<detailed_description>The purpose study assess safety tolerability profile ATYR1940 treatment adult patient molecularly define genetic muscular dystrophy , additionally explore pharmacokinetics biologic activity ATYR1940 adult patient molecularly define genetic muscular dystrophy . Patients successfully complete parent study ( NCT02239224 ) eligible enrollment long-term extension study .</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Facioscapulohumeral</mesh_term>
	<criteria>Patient establish , geneticallyconfirmed , diagnosis facioscapulohumeral dystrophy clinical finding meet exist criterion Patient male female age 18 65 year , inclusive . Patients previously participate Study ATYR1940C002 meet entry criterion current study eligible enrollment . Patient currently receive treatment immunomodulatory agent history treatment , include target biological therapy ( e.g. , etanercept , omalizumab ) within 3 month Baseline ; corticosteroid within 4 week Baseline ; nonsteroidal antiinflammatory agent ( NSAIDs ) within 2 week Baseline . Patient severe retinopathy . Patient history obstructive restrictive lung disease ( include interstitial lung disease , pulmonary fibrosis , asthma ) , evidence interstitial lung disease Screening chest radiograph . Patient evidence clinically significant cardiovascular , pulmonary , hepatic , renal , hematological , metabolic , dermatological , gastrointestinal disease , condition require immediate surgical intervention treatment may allow safe participation . Patient use investigational product device ( mobility assistance device ) within 30 day Baseline . If female childbearing potential ( premenopausal surgically sterile ) , patient positive pregnancy test Screening unwilling use contraception time Screening 1month Followup visit . Acceptable method birth control include abstinence , barrier method , hormone , intrauterine device . If male , patient unwilling use condom plus spermicide sexual intercourse time Screening 1 month Followup visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>